{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:30:48Z","timestamp":1790973048113,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012695","name":"Beatrice and Samuel A. Seaver Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012695","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SHANK2 foundation"},{"name":"Developmental Synaptopathies Consortium","award":["U54NS092090"],"award-info":[{"award-number":["U54NS092090"]}]},{"name":"Developmental Synaptopathies Consortium","award":["U54NS092090"],"award-info":[{"award-number":["U54NS092090"]}]},{"name":"Developmental Synaptopathies Consortium","award":["U54NS092090"],"award-info":[{"award-number":["U54NS092090"]}]},{"name":"Developmental Synaptopathies Consortium","award":["U54NS092090"],"award-info":[{"award-number":["U54NS092090"]}]},{"name":"Developmental Synaptopathies Consortium","award":["U54NS092090"],"award-info":[{"award-number":["U54NS092090"]}]},{"name":"Developmental Synaptopathies Consortium","award":["U54NS092090"],"award-info":[{"award-number":["U54NS092090"]}]},{"name":"Developmental Synaptopathies Consortium","award":["U54NS092090"],"award-info":[{"award-number":["U54NS092090"]}]},{"name":"RDCRN Data Management and Coordinating Center","award":["U2CTR002818"],"award-info":[{"award-number":["U2CTR002818"]}]},{"name":"RDCRN Data Management and Coordinating Center","award":["U2CTR002818"],"award-info":[{"award-number":["U2CTR002818"]}]},{"name":"RDCRN Data Management and Coordinating Center","award":["U2CTR002818"],"award-info":[{"award-number":["U2CTR002818"]}]},{"name":"RDCRN Data Management and Coordinating Center","award":["U2CTR002818"],"award-info":[{"award-number":["U2CTR002818"]}]},{"name":"RDCRN Data Management and Coordinating Center","award":["U2CTR002818"],"award-info":[{"award-number":["U2CTR002818"]}]},{"name":"RDCRN Data Management and Coordinating Center","award":["U2CTR002818"],"award-info":[{"award-number":["U2CTR002818"]}]},{"name":"RDCRN Data Management and Coordinating Center","award":["U2CTR002818"],"award-info":[{"award-number":["U2CTR002818"]}]},{"name":"Intramural Research Program of the NIMH","award":["ZICMH002961"],"award-info":[{"award-number":["ZICMH002961"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurodevelop Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>SHANK2 disorder is a rare neurodevelopmental disorder caused by a deletion or pathogenic sequence variant of the <jats:italic>SHANK2<\/jats:italic> gene and is associated with autism spectrum disorder (ASD), intellectual disability (ID), and developmental delay. To date, research in <jats:italic>SHANK2<\/jats:italic> has focused on laboratory-based in vivo and in vitro studies with few prospective clinical studies in humans.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A remote assessment battery was comprised of caregiver interviews with a psychiatrist, psychologists, and a genetic counselor, caregiver-reports, and review of records. Results from this cohort were reported using descriptive statistics. An age-matched sample of participants with <jats:italic>SHANK3<\/jats:italic> haploinsufficiency (Phelan-McDermid syndrome, PMS) was used to compare adaptive behavior between the two groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>All ten participants demonstrated delays in adaptive behavior, with most motor skills preserved and a weakness in communication. According to parent report, 90% of participants carried a formal diagnosis of ASD, 50% of participants carried a diagnosis of attention-deficit\/hyperactivity disorder (ADHD), and mild-to-moderate developmental delays were noted. Sensory hyperreactivity and seeking behaviors were more pronounced than sensory hyporeactivity. Medical features included hypotonia, recurrent ear infections, and gastrointestinal abnormalities. No similar facial dysmorphic features were observed. Compared to PMS participants, individuals with SHANK2 disorder had significantly higher adaptive functioning.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Consistent with previous studies of SHANK2 disorder, these results indicate mild to moderate developmental impairment. Overall, SHANK2 disorder is associated with developmental and adaptive functioning delays, high rates of autism, including sensory symptoms and repetitive behaviors, and ADHD. This study was limited by its remote nature, diverse age range, and the homogeneous racial and ethnic sample. Future studies should examine larger, diverse cohorts, add cognitive testing, capture longitudinal data, and include in-person assessments.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s11689-025-09600-0","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T09:43:57Z","timestamp":1746006237000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Protein-truncating variants and deletions of SHANK2 are associated with autism spectrum disorder and other neurodevelopmental concerns"],"prefix":"10.1186","volume":"17","author":[{"given":"Hailey","family":"Silver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rori","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige M.","family":"Siper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Zweifach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Soufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Berry-Kravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latha Valluripalli","family":"Soorya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Thurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kolevzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy E.","family":"Grice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Buxbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"9600_CR1","doi-asserted-by":"crossref","unstructured":"Savatt JM, Myers SM. Genetic testing in neurodevelopmental disorders. Front Pediatr. 2021;19(9).","DOI":"10.3389\/fped.2021.526779"},{"issue":"11","key":"9600_CR2","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/GIM.0b013e3181f8baad","volume":"12","author":"M Manning","year":"2010","unstructured":"Manning M, Hudgins L. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet Med. 2010;12(11):742\u20135.","journal-title":"Genet Med"},{"issue":"8","key":"9600_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJMra1114194","volume":"366","author":"HC Mefford","year":"2012","unstructured":"Mefford HC, Batshaw ML, Hoffman EP. Genomics, intellectual disability, and autism. N Engl J Med. 2012;366(8):733\u201343.","journal-title":"N Engl J Med"},{"issue":"11","key":"9600_CR4","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1038\/s41436-019-0554-6","volume":"21","author":"S Srivastava","year":"2019","unstructured":"Srivastava S, Love-Nichols JA, Dies KA, Ledbetter DH, Martin CL, Chung WK, et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019;21(11):2413\u201321.","journal-title":"Genet Med"},{"issue":"18","key":"9600_CR5","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1001\/jama.2014.14601","volume":"312","author":"Y Yang","year":"2014","unstructured":"Yang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014;312(18):1870\u20139.","journal-title":"JAMA"},{"issue":"1","key":"9600_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13229-021-00465-3","volume":"12","author":"B Mahjani","year":"2021","unstructured":"Mahjani B, De Rubeis S, Gustavsson Mahjani C, Mulhern M, Xu X, Klei L, et al. Prevalence and phenotypic impact of rare potentially damaging variants in autism spectrum disorder. Mol Autism. 2021;12(1):65.","journal-title":"Mol Autism"},{"issue":"5","key":"9600_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/gim.2013.32","volume":"15","author":"GB Schaefer","year":"2013","unstructured":"Schaefer GB, Mendelsohn NJ. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. Genet Med. 2013;15(5):399\u2013407.","journal-title":"Genet Med"},{"issue":"9","key":"9600_CR8","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41588-022-01104-0","volume":"54","author":"JM Fu","year":"2022","unstructured":"Fu JM, Satterstrom FK, Peng M, Brand H, Collins RL, Dong S, et al. Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. Nat Genet. 2022;54(9):1320\u201331.","journal-title":"Nat Genet"},{"issue":"4","key":"9600_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/ng.3792","volume":"49","author":"HA Stessman","year":"2017","unstructured":"Stessman HA, Xiong B, Coe BP, Wang T, Hoekzema K, Fenckova M, et al. Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases. Nat Genet. 2017;49(4):515\u201326.","journal-title":"Nat Genet"},{"issue":"3","key":"9600_CR10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.cell.2019.12.036","volume":"180","author":"FK Satterstrom","year":"2020","unstructured":"Satterstrom FK, Kosmicki JA, Wang J, Breen MS, De Rubeis S, An JY, et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell. 2020;180(3):568\u2013e84523.","journal-title":"Cell"},{"issue":"1","key":"9600_CR11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1186\/s12864-021-08227-4","volume":"22","author":"N Maia","year":"2021","unstructured":"Maia N, Nabais S\u00e1 MJ, Melo-Pires M, de Brouwer APM, Jorge P. Intellectual disability genomics: current State, pitfalls and future challenges. BMC Genomics. 2021;22(1):909.","journal-title":"BMC Genomics"},{"issue":"20","key":"9600_CR12","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1206524","volume":"367","author":"J de Ligt","year":"2012","unstructured":"de Ligt J, Willemsen MH, van Bon BW, Kleefstra T, Yntema HG, Kroes T, et al. Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med. 2012;367(20):1921\u20139.","journal-title":"N Engl J Med"},{"issue":"24","key":"9600_CR13","doi-asserted-by":"publisher","first-page":"13439","DOI":"10.3390\/ijms222413439","volume":"22","author":"LP Bruno","year":"2021","unstructured":"Bruno LP, Doddato G, Valentino F, Baldassarri M, Tita R, Fallerini C, et al. New candidates for autism\/intellectual disability identified by whole-exome sequencing. Int J Mol Sci. 2021;22(24):13439.","journal-title":"Int J Mol Sci"},{"issue":"7831","key":"9600_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41586-020-2832-5","volume":"586","author":"J Kaplanis","year":"2020","unstructured":"Kaplanis J, Samocha KE, Wiel L, Zhang Z, Arvai KJ, Eberhardt RY, et al. Evidence for 28 genetic disorders discovered by combining healthcare and research data. Nature. 2020;586(7831):757\u201362.","journal-title":"Nature"},{"issue":"3","key":"9600_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrn.2016.183","volume":"18","author":"P Monteiro","year":"2017","unstructured":"Monteiro P, Feng G. SHANK proteins: roles at the synapse and in autism spectrum disorder. Nat Rev Neurosci. 2017;18(3):147\u201357.","journal-title":"Nat Rev Neurosci"},{"issue":"6","key":"9600_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/ng.589","volume":"42","author":"S Berkel","year":"2010","unstructured":"Berkel S, Marshall CR, Weiss B, Howe J, Roeth R, Moog U, et al. Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat Genet. 2010;42(6):489\u201391.","journal-title":"Nat Genet"},{"key":"9600_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13229-018-0205-9","volume":"9","author":"S De Rubeis","year":"2018","unstructured":"De Rubeis S, Siper PM, Durkin A, Weissman J, Muratet F, Halpern D, et al. Delineation of the genetic and clinical spectrum of Phelan-McDermid syndrome caused by SHANK3 point mutations. Mol Autism. 2018;9:31.","journal-title":"Mol Autism"},{"issue":"1","key":"9600_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2040-2392-4-18","volume":"4","author":"L Soorya","year":"2013","unstructured":"Soorya L, Kolevzon A, Zweifach J, Lim T, Dobry Y, Schwartz L, et al. Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency. Mol Autism. 2013;4(1):18.","journal-title":"Mol Autism"},{"issue":"7","key":"9600_CR19","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1007\/s10803-016-2754-0","volume":"46","author":"AM Mieses","year":"2016","unstructured":"Mieses AM, Tavassoli T, Li E, Soorya L, Lurie S, Wang AT, et al. Brief report: sensory reactivity in children with Phelan-McDermid syndrome. J Autism Dev Disord. 2016;46(7):2508\u201313.","journal-title":"J Autism Dev Disord"},{"issue":"7","key":"9600_CR20","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3390\/genes12070977","volume":"12","author":"T Tavassoli","year":"2021","unstructured":"Tavassoli T, Layton C, Levy T, Rowe M, George-Jones J, Zweifach J, et al. Sensory reactivity phenotype in Phelan-McDermid syndrome is distinct from idiopathic ASD. Genes (Basel). 2021;12(7):977.","journal-title":"Genes (Basel)"},{"issue":"4","key":"9600_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/hmg\/ddab280","volume":"31","author":"T Levy","year":"2022","unstructured":"Levy T, Foss-Feig JH, Betancur C, Siper PM, Trelles-Thorne MP, Halpern D, et al. Strong evidence for genotype-phenotype correlations in Phelan-McDermid syndrome: results from the developmental synaptopathies consortium. Hum Mol Genet. 2022;31(4):625\u201337.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"9600_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13229-022-00518-1","volume":"13","author":"M Yun","year":"2022","unstructured":"Yun M, Kim E, Jung MW. Enhanced fear limits behavioral flexibility in Shank2-deficient mice. Mol Autism. 2022;13(1):40.","journal-title":"Mol Autism"},{"issue":"1","key":"9600_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13041-023-01025-x","volume":"16","author":"JE Choi","year":"2023","unstructured":"Choi JE, Kaang BK. Increased social interaction in Shank2-deficient mice following acute social isolation. Mol Brain. 2023;16(1):35.","journal-title":"Mol Brain"},{"issue":"1","key":"9600_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13229-023-00552-7","volume":"14","author":"F Olde Heuvel","year":"2023","unstructured":"Olde Heuvel F, Ouali Alami N, Aousji O, Pogatzki-Zahn E, Zahn PK, Wilhelm H, et al. Shank2 identifies a subset of glycinergic neurons involved in altered nociception in an autism model. Mol Autism. 2023;14(1):21.","journal-title":"Mol Autism"},{"issue":"7402","key":"9600_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nature11208","volume":"486","author":"H Won","year":"2012","unstructured":"Won H, Lee HR, Gee HY, Mah W, Kim JI, Lee J, et al. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature. 2012;486(7402):261\u20135.","journal-title":"Nature"},{"issue":"7","key":"9600_CR26","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.biopsych.2018.09.025","volume":"85","author":"C Chung","year":"2019","unstructured":"Chung C, Ha S, Kang H, Lee J, Um SM, Yan H, et al. Early Correction of N-Methyl-D-Aspartate receptor function improves autistic-like social behaviors in adult Shank2-\/- mice. Biol Psychiatry. 2019;85(7):534\u201343.","journal-title":"Biol Psychiatry"},{"key":"9600_CR27","doi-asserted-by":"publisher","first-page":"110973","DOI":"10.1016\/j.pnpbp.2024.110973","volume":"132","author":"JC Kreutzmann","year":"2024","unstructured":"Kreutzmann JC, Kahl E, Fendt M. Sex-specific modulation of safety learning in Shank2-deficient mice. Prog Neuropsychopharmacol Biol Psychiatry. 2024;132:110973.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"9600_CR28","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3389\/fnmol.2018.00240","volume":"11","author":"A Eltokhi","year":"2018","unstructured":"Eltokhi A, Rappold G, Sprengel R. Distinct phenotypes of Shank2 mouse models reflect neuropsychiatric spectrum disorders of human patients with SHANK2 variants. Front Mol Neurosci. 2018;11:240.","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"9600_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13041-020-00595-4","volume":"13","author":"YS Lee","year":"2020","unstructured":"Lee YS, Yu NK, Chun J, Yang JE, Lim CS, Kim H, et al. Identification of a novel Shank2 transcriptional variant in Shank2 knockout mouse model of autism spectrum disorder. Mol Brain. 2020;13(1):54.","journal-title":"Mol Brain"},{"issue":"17","key":"9600_CR30","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1523\/JNEUROSCI.2684-17.2018","volume":"38","author":"R Kim","year":"2018","unstructured":"Kim R, Kim J, Chung C, Ha S, Lee S, Lee E, et al. Cell-type-specific Shank2 deletion in mice leads to differential synaptic and behavioral phenotypes. J Neurosci. 2018;38(17):4076\u201392.","journal-title":"J Neurosci"},{"key":"9600_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3389\/fnmol.2018.00209","volume":"11","author":"S Lee","year":"2018","unstructured":"Lee S, Lee E, Kim R, Kim J, Lee S, Park H, et al. Shank2 deletion in parvalbumin neurons leads to moderate hyperactivity, enhanced self-grooming and suppressed seizure susceptibility in mice. Front Mol Neurosci. 2018;11:209.","journal-title":"Front Mol Neurosci"},{"issue":"12","key":"9600_CR32","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/mp.2014.172","volume":"20","author":"S Peykov","year":"2015","unstructured":"Peykov S, Berkel S, Schoen M, Weiss K, Degenhardt F, Strohmaier J, et al. Identification and functional characterization of rare SHANK2 variants in schizophrenia. Mol Psychiatry. 2015;20(12):1489\u201398.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"9600_CR33","doi-asserted-by":"publisher","first-page":"e10711","DOI":"10.1002\/jbm4.10711","volume":"7","author":"M Ahmad","year":"2022","unstructured":"Ahmad M, Stirmlinger N, Jan I, Stifel U, Lee S, Weingandt M, et al. Downregulation of the autism spectrum disorder gene Shank2 decreases bone mass in male mice. JBMR Plus. 2022;7(2):e10711.","journal-title":"JBMR Plus"},{"issue":"3","key":"9600_CR34","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajmg.a.38075","volume":"173","author":"CA Marcou","year":"2017","unstructured":"Marcou CA, Studinski Jones AL, Murphree MI, Kirmani S, Hoppman NL. De Novo 11q deletion including SHANK2 in a patient with global developmental delay. Am J Med Genet A. 2017;173(3):801\u20135.","journal-title":"Am J Med Genet A"},{"issue":"2","key":"9600_CR35","doi-asserted-by":"publisher","first-page":"e1002521","DOI":"10.1371\/journal.pgen.1002521","volume":"8","author":"CS Leblond","year":"2012","unstructured":"Leblond CS, Heinrich J, Delorme R, Proepper C, Betancur C, Huguet G, et al. Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders. PLoS Genet. 2012;8(2):e1002521.","journal-title":"PLoS Genet"},{"issue":"4","key":"9600_CR36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000322054","volume":"1","author":"A Wischmeijer","year":"2011","unstructured":"Wischmeijer A, Magini P, Giorda R, Gnoli M, Ciccone R, Cecconi L, et al. Olfactory receptor-related duplicons mediate a microdeletion at 11q13.2q13.4 associated with a syndromic phenotype. Mol Syndromol. 2011;1(4):176\u201384.","journal-title":"Mol Syndromol"},{"issue":"2","key":"9600_CR37","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/hmg\/ddr470","volume":"21","author":"S Berkel","year":"2012","unstructured":"Berkel S, Tang W, Trevi\u00f1o M, Vogt M, Obenhaus HA, Gass P, et al. Inherited and de Novo SHANK2 variants associated with autism spectrum disorder impair neuronal morphogenesis and physiology. Hum Mol Genet. 2012;21(2):344\u201357.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"9600_CR38","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/humu.23724","volume":"40","author":"WZ Zhou","year":"2019","unstructured":"Zhou WZ, Zhang J, Li Z, Lin X, Li J, Wang S, et al. Targeted resequencing of 358 candidate genes for autism spectrum disorder in a Chinese cohort reveals diagnostic potential and genotype-phenotype correlations. Hum Mutat. 2019;40(6):801\u201315.","journal-title":"Hum Mutat"},{"key":"9600_CR39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13229-018-0247-z","volume":"9","author":"H Guo","year":"2018","unstructured":"Guo H, Wang T, Wu H, Long M, Coe BP, Li H, et al. Inherited and multiple de Novo mutations in autism\/developmental delay risk genes suggest a multifactorial model. Mol Autism. 2018;9:64.","journal-title":"Mol Autism"},{"issue":"1","key":"9600_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13073-017-0433-1","volume":"9","author":"KM Bowling","year":"2017","unstructured":"Bowling KM, Thompson ML, Amaral MD, Finnila CR, Hiatt SM, Engel KL, et al. Genomic diagnosis for children with intellectual disability and\/or developmental delay. Genome Med. 2017;9(1):43.","journal-title":"Genome Med"},{"issue":"9","key":"9600_CR41","doi-asserted-by":"publisher","first-page":"e1004580","DOI":"10.1371\/journal.pgen.1004580","volume":"10","author":"CS Leblond","year":"2014","unstructured":"Leblond CS, Nava C, Polge A, Gauthier J, Huguet G, Lumbroso S, et al. Meta-analysis of SHANK mutations in autism spectrum disorders: A gradient of severity in cognitive impairments. PLoS Genet. 2014;10(9):e1004580.","journal-title":"PLoS Genet"},{"issue":"7304","key":"9600_CR42","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nature09146","volume":"466","author":"D Pinto","year":"2010","unstructured":"Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. 2010;466(7304):368\u201372.","journal-title":"Nature"},{"issue":"12","key":"9600_CR43","doi-asserted-by":"publisher","first-page":"104072","DOI":"10.1016\/j.ejmg.2020.104072","volume":"63","author":"R Caumes","year":"2020","unstructured":"Caumes R, Smol T, Thuillier C, Balerdi M, Lestienne-Roche C, Manouvrier-Hanu S, Ghoumid J. Phenotypic spectrum of SHANK2-related neurodevelopmental disorder. Eur J Med Genet. 2020;63(12):104072.","journal-title":"Eur J Med Genet"},{"issue":"4","key":"9600_CR44","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3390\/genes13040688","volume":"13","author":"G Doddato","year":"2022","unstructured":"Doddato G, Fabbiani A, Scandurra V, Canitano R, Mencarelli MA, Renieri A, Ariani F. Identification of a novel SHANK2 pathogenic variant in a patient with a neurodevelopmental disorder. Genes. 2022;13(4):688.","journal-title":"Genes"},{"issue":"1","key":"9600_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41525-024-00408-w","volume":"9","author":"A AlMail","year":"2024","unstructured":"AlMail A, Jamjoom A, Pan A, Feng MY, Chau V, D\u2019Gama AM, et al. Consensus reporting guidelines to address gaps in descriptions of ultra-rare genetic conditions. NPJ Genom Med. 2024;9(1):27.","journal-title":"NPJ Genom Med"},{"issue":"15","key":"9600_CR46","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1093\/hmg\/ddac018","volume":"31","author":"T Levy","year":"2022","unstructured":"Levy T, Lerman B, Halpern D, Frank Y, Layton C, Zweifach J, et al. CHAMP1 disorder is associated with a complex neurobehavioral phenotype including autism, ADHD, repetitive behaviors and sensory symptoms. Hum Mol Genet. 2022;31(15):2582\u201394.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"9600_CR47","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1017\/S0954579413000874","volume":"26","author":"A Thurm","year":"2014","unstructured":"Thurm A, Manwaring SS, Luckenbaugh DA, Lord C, Swedo SE. Patterns of skill attainment and loss in young children with autism. Dev Psychopathol. 2014;26(1):203\u201314.","journal-title":"Dev Psychopathol"},{"issue":"3","key":"9600_CR48","doi-asserted-by":"publisher","first-page":"e2021052138","DOI":"10.1542\/peds.2021-052138","volume":"149","author":"JM Zubler","year":"2022","unstructured":"Zubler JM, Wiggins LD, Macias MM, Whitaker TM, Shaw JS, Squires JK, et al. Evidence-informed milestones for developmental surveillance tools. Pediatrics. 2022;149(3):e2021052138.","journal-title":"Pediatrics"},{"key":"9600_CR49","volume-title":"Developmental profile 4","author":"GD Alpern","year":"2020","unstructured":"Alpern GD. Developmental profile 4. Torrance, CA: Western Psychological Services; 2020."},{"key":"9600_CR50","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1007\/978-0-387-79948-3_1602","volume-title":"Encyclopedia of clinical neuropsychology","author":"SS Sparrow","year":"2011","unstructured":"Sparrow SS. Vineland adaptive behavior scales. In: Kreutzer JS, DeLuca J, Caplan B, editors. Encyclopedia of clinical neuropsychology. New York, NY: Springer New York; 2011. pp. 2618\u201321."},{"key":"9600_CR51","volume-title":"Sensory assessment for neurodevelopmental disorders","author":"P Siper","year":"2021","unstructured":"Siper P, Tavassoli T. Sensory assessment for neurodevelopmental disorders. Wood Dale: Stoelting Co; 2021."},{"issue":"1","key":"9600_CR52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5014\/ajot.51.1.25","volume":"51","author":"W Dunn","year":"1997","unstructured":"Dunn W, Westman K. The sensory profile: the performance of a National sample of children without disabilities. Am J Occup Ther. 1997;51(1):25\u201334.","journal-title":"Am J Occup Ther"},{"key":"9600_CR53","first-page":"429","volume-title":"The child behavior checklist and related instruments. The use of psychological testing for treatment planning and outcomes assessment","author":"TM Achenbach","year":"1999","unstructured":"Achenbach TM. The child behavior checklist and related instruments. The use of psychological testing for treatment planning and outcomes assessment. 2nd ed. Mahwah, NJ, US: Lawrence Erlbaum Associates; 1999. pp. 429\u201366.","edition":"2"},{"key":"9600_CR54","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/978-1-4419-1698-3_1632","volume-title":"Encyclopedia of autism spectrum disorders","author":"MG Aman","year":"2013","unstructured":"Aman MG. Aberrant behavior checklist. In: Volkmar FR, editor. Encyclopedia of autism spectrum disorders. New York, NY: Springer New York; 2013. pp. 10\u20137."},{"issue":"5","key":"9600_CR55","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10803-006-0213-z","volume":"37","author":"KS Lam","year":"2007","unstructured":"Lam KS, Aman MG. The repetitive behavior scale-revised: independent validation in individuals with autism spectrum disorders. J Autism Dev Disord. 2007;37(5):855\u201366.","journal-title":"J Autism Dev Disord"},{"key":"9600_CR56","doi-asserted-by":"publisher","first-page":"101474","DOI":"10.1016\/j.rasd.2019.101474","volume":"70","author":"TW Frazier","year":"2020","unstructured":"Frazier TW, Hyland AC, Markowitz LA, Speer LL, Diekroger EA. Psychometric evaluation of the revised child and family quality of life questionnaire (CFQL-2). Res Autism Spectr Disord. 2020;70:101474.","journal-title":"Res Autism Spectr Disord"},{"key":"9600_CR57","unstructured":"Five do\u2019s and don\u2019ts of potty training your toddler. https:\/\/health.ucdavis.edu\/children\/patient-education\/potty-training-children#:~:text=Most children complete potty training,three months before boys do. Accessed 20 September 2024."},{"key":"9600_CR58","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. APA; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"11","key":"9600_CR59","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/jcpp.13492","volume":"62","author":"J Wickstrom","year":"2021","unstructured":"Wickstrom J, Farmer C, Green Snyder L, Mitz AR, Sanders SJ, Bishop S, Thurm A. Patterns of delay in early gross motor and expressive Language milestone attainment in probands with genetic conditions versus idiopathic ASD from SFARI registries. J Child Psychol Psychiatr. 2021;62(11):1297\u2013307.","journal-title":"J Child Psychol Psychiatr"},{"issue":"8","key":"9600_CR60","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/aur.2299","volume":"13","author":"K Gergoudis","year":"2020","unstructured":"Gergoudis K, Weinberg A, Templin J, Farmer C, Durkin A, Weissman J, et al. Psychometric study of the social responsiveness scale in Phelan-McDermid syndrome. Autism Res. 2020;13(8):1383\u201396.","journal-title":"Autism Res"},{"issue":"5","key":"9600_CR61","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/01.yco.0000179483.62391.12","volume":"18","author":"C Mohr","year":"2005","unstructured":"Mohr C, Gray KM. Assessment in intellectual disability. Curr Opin Psychiatry. 2005;18(5):476\u201383.","journal-title":"Curr Opin Psychiatry"},{"issue":"7","key":"9600_CR62","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1080\/13854046.2017.1413211","volume":"32","author":"L Soorya","year":"2018","unstructured":"Soorya L, Leon J, Trelles MP, Thurm A. Framework for assessing individuals with rare genetic disorders associated with profound intellectual and multiple disabilities (PIMD): the example of Phelan McDermid syndrome. Clin Neuropsychol. 2018;32(7):1226\u201355.","journal-title":"Clin Neuropsychol"},{"issue":"1","key":"9600_CR63","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13229-021-00469-z","volume":"12","author":"MP Trelles","year":"2021","unstructured":"Trelles MP, Levy T, Lerman B, Siper P, Lozano R, Halpern D, et al. Individuals with FOXP1 syndrome present with a complex neurobehavioral profile with high rates of ADHD, anxiety, repetitive behaviors, and sensory symptoms. Mol Autism. 2021;12(1):61.","journal-title":"Mol Autism"},{"key":"9600_CR64","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.pediatrneurol.2022.10.009","volume":"138","author":"T Levy","year":"2023","unstructured":"Levy T, Siper PM, Lerman B, Halpern D, Zweifach J, Belani P, et al. DDX3X syndrome: summary of findings and recommendations for evaluation and care. Pediatr Neurol. 2023;138:87\u201394.","journal-title":"Pediatr Neurol"},{"issue":"5","key":"9600_CR65","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1542\/peds.2013-4301","volume":"134","author":"SA Kidd","year":"2014","unstructured":"Kidd SA, Lachiewicz A, Barbouth D, Blitz RK, Delahunty C, McBrien D, et al. Fragile X syndrome: a review of associated medical problems. Pediatrics. 2014;134(5):995\u20131005.","journal-title":"Pediatrics"},{"issue":"5","key":"9600_CR66","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41436-020-01076-8","volume":"23","author":"AM Muir","year":"2021","unstructured":"Muir AM, Gardner JF, van Jaarsveld RH, de Lange IM, van der Smagt JJ, Wilson GN, et al. Variants in GNAI1 cause a syndrome associated with variable features including developmental delay, seizures, and hypotonia. Genet Med. 2021;23(5):881\u20137.","journal-title":"Genet Med"}],"container-title":["Journal of Neurodevelopmental Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-025-09600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11689-025-09600-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-025-09600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T11:04:44Z","timestamp":1746011084000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneurodevdisorders.biomedcentral.com\/articles\/10.1186\/s11689-025-09600-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9600"],"URL":"https:\/\/doi.org\/10.1186\/s11689-025-09600-0","relation":{},"ISSN":["1866-1955"],"issn-type":[{"value":"1866-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Icahn School of Medicine at Mount Sinai\u2019s Institutional Review Board (IRB) approved the study. Caregivers or legal guardians of the participants provided informed consent, and assent was obtained when applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.K. receives research support from AMO Pharma and consults for Acadia, Alkermes, Neuren, and GW Pharma. He serves on Scientific Advisory Boards for Ovid Therapeutics, Jaguar Therapeutics, and Ritrova Therapeutics. P.M.S. and Mount Sinai licensed the SAND developed by P.M.S. to Stoelting, Co. J.D.B. holds a patent for IGF-1 in Phelan-McDermid syndrome, holds an honorary professorship from Aarhus University Denmark, and is a journal editor for Springer Nature. M.S. reports grant support from Biogen, Astellas, Neurvati Neurosciences, Bridgebio, and Aucta. He has served on scientific advisory boards for Neurogene, Jaguar Gene Therapy and Noema. EBK has received funding from Seaside Therapeutics, Novartis, Roche, Alcobra, Neuren, Cydan, Fulcrum, GW, Neurotrope, Marinus, Zynerba, BioMarin, Ovid, Retrophin, AMO, Yamo, Acadia, Avexis, Ionis, Ultragenyx, Lumos, GeneTx, and Vtesse\/Sucampo\/Mallinkcrodt Pharmaceuticals to consult on trial design or development strategies and\/or conduct clinical trials in FXS or other NDDs or neurodegenerative disorders, and from Asuragen Inc to develop testing standards for FMR1 testing. All funding to EBK is directed to Rush University Medical Center to support rare disease programs. EBK receives no personal funds. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}